Clinical Insights in Geriatrics: Successfully Diagnosing and Managing Overactive Bladder in Older Adults to Optimize Outcomes
Release Date: November-18-11
Credit Expiration Date: November-18-12
Senior care providers including physicians, nurses, consultant pharmacists, and others interested in the care of older patients with OAB.
Family Physicians: 0.50 Prescribed credit
Nurses: 0.75 Contact Hours
Pharmacists: 0.75 Contact Hour (0.075 CEU)
Overactive bladder (OAB) is the most common cause of urinary incontinence or loss of bladder control in adults and affects approximately 33 million Americans. While OAB affects people of all ages, the medical issue of OAB is of particular importance in the older adult population with prevalence greatly increasing in older individuals. The symptoms of OAB—urge urinary incontinence (UI), urgency, and urinary frequency—often lead to further medical and psychological problems and can have a devastating impact on quality of life.
Primary and long-term care physicians, pharmacists, nursing directors, physician assistants, and nurse practitioners have the opportunity to improve outcomes for older adults with OAB by more thoroughly identifying patients who suffer from OAB, by more consistently providing effective OAB treatment, and by increasing the use of strategies to promote patient adherence to OAB treatment recommendations. The goal of this continuing medical education activity is to expand the ability of primary care providers and other senior care clinicians to provide optimal care for older adults experiencing OAB, ultimately improving outcomes for the many older individuals who suffer from OAB.
Tomas L. Griebling, MD, MPH, FACS, FGSA, AGSF
John P. Wolf 33° Masonic Distinguished Professor of Urology
Vice-Chair - Department of Urology
Faculty Associate - The Landon Center on Aging
Assistant Dean for Student Affairs & Director - Orr Academic Society
The University of Kansas
Kansas City, KS
Angela K. Golden, DNP, FNP-C, FAANP
Owner, NP From Home, LLC
Northern Arizona University
Thomas E. Lackner, PharmD, CGP, FASCP
Director of Pharmacy Services
Geriatric Care Services
Eden Prairie, MN
Mary Campagnolo, MD, MBA, FAAFP, DABFM, CAQ-Geriatrics
Virtua-Lumberton Family Physicians
It is the policy of the AAFP, ASCP, and NADONA to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Griebling discloses the following relationship: Clinical Investigator: Medtronic and Pfizer.
Dr. Golden has no relevant financial conflicts to disclose.
Dr. Lackner has no relevant financial conflicts to disclose.
Dr. Campagnolo has no relevant financial conflicts to disclose.
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.
Ms. Barrett has no relevant financial conflicts to disclose.
Ms. Dornberger has no relevant financial conflicts to disclose.
Ms. Klobnak discloses the following relationship: Stock Ownership: Teva Pharmaceuticals.
Dr. Paczolt has no relevant financial conflicts to disclose.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This Enduring Material activity, Successfully Diagnosing and Managing Overactive Bladder in Older Adults to Optimize Outcomes, has been reviewed and is acceptable for up to 0.50 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins November 18, 2011. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-11-156-H01-P, has been assigned 0.75 Contact Hour (0.075 CEU).
Accreditation received from ASCP November 11, 2011.
NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1088. This activity provides 0.75 contact hour by NADONA/LTC.
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing education credit. Credit will be awarded for a score of >80%, and a statement may be printed immediately after passing the post-test.
There is no fee to participate in this educational activity.
This activity is supported by an educational grant from Pfizer Inc.
This activity is supported by an educational grant from Astellas Pharma Global Development, Inc.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, ASCP, NJAFP, NADONA, Pfizer Inc, or Astellas Pharma Global Development, Inc.. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.